See more : Haier Smart Home Co., Ltd. (600690.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Fractyl Health, Inc. Common Stock (GUTS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fractyl Health, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hiday Hidaka Corp. (7611.T) Income Statement Analysis – Financial Results
- Extendicare Inc. (EXE.TO) Income Statement Analysis – Financial Results
- Compodium International AB (publ) (COMPDM.ST) Income Statement Analysis – Financial Results
- River Hawk Aviation, Inc. (RHWI) Income Statement Analysis – Financial Results
- Bolloré SE (BOL.PA) Income Statement Analysis – Financial Results
Fractyl Health, Inc. Common Stock (GUTS)
About Fractyl Health, Inc. Common Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 120.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 77.00K | 452.00K | 676.00K | 770.00K | 893.00K |
| Gross Profit | 43.00K | -452.00K | -676.00K | -770.00K | -893.00K |
| Gross Profit Ratio | 35.83% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 38.04M | 34.35M | 26.44M | 22.43M | 20.89M |
| General & Administrative | 0.00 | 15.03M | 10.49M | 6.53M | 9.03M |
| Selling & Marketing | 0.00 | -452.00K | -676.00K | -770.00K | -893.00K |
| SG&A | 12.84M | 14.58M | 9.82M | 5.76M | 8.14M |
| Other Expenses | 0.00 | 2.31M | -9.00K | -1.00K | 0.00 |
| Operating Expenses | 50.88M | 48.93M | 36.25M | 28.19M | 29.03M |
| Cost & Expenses | 50.96M | 49.39M | 36.93M | 28.96M | 29.92M |
| Interest Income | 1.26M | 797.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 1.44M | 1.50M | 635.00K |
| Depreciation & Amortization | 286.00K | 452.00K | 676.00K | 770.00K | 893.00K |
| EBITDA | -50.55M | -48.93M | -36.25M | -28.19M | -29.03M |
| EBITDA Ratio | -42,125.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -50.84M | -49.39M | -36.93M | -28.96M | -29.92M |
| Operating Income Ratio | -42,363.33% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -26.26M | 2.93M | -1.81M | -1.52M | -673.00K |
| Income Before Tax | -77.09M | -46.45M | -38.74M | -30.48M | -30.59M |
| Income Before Tax Ratio | -64,242.50% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -77.09M | -46.45M | -38.74M | -30.48M | -30.59M |
| Net Income Ratio | -64,242.50% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.98 | -0.98 | -0.81 | -0.64 | -0.64 |
| EPS Diluted | -1.98 | -0.98 | -0.81 | -0.64 | -0.64 |
| Weighted Avg Shares Out | 47.61M | 47.61M | 47.61M | 47.61M | 47.61M |
| Weighted Avg Shares Out (Dil) | 47.61M | 47.61M | 47.61M | 47.61M | 47.61M |
Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024
BURLINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report...
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
BURLINGTON, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that Dr. Harith Rajagopalan,...
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
Company will accelerate Revita® weight maintenance clinical study REMAIN-1; open label data from REVEAL-1 cohort expected in Q4 2024 and mid-point data analysis for REMAIN-1 anticipated in Q2 2025 Company expands Revita type 2 diabetes clinical study REVITALIZE-1, expanding eligibility;...
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's 84th Scientific Sessions
Single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model Rejuva also prevented weight and glycemic rebound after semaglutide withdrawal Data provide first demonstration that Rejuva treatment has potential to mimic natural...
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p
Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript
Fractyl Health, Inc. (NASDAQ:GUTS ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Stephen Jasper - Gilmartin Group Harith Rajagopalan - Co-founder and CEO Lisa Davidson - CFO Timothy Kieffer - Chief Scientific Officer Adrian...
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
Initiation of Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 based drugs expected in the second half of 2024 Topline data from Revitalize-1 pivotal study in patients with inadequately controlled T2D anticipated in the...
Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
First 14 participants with at least six months of follow up continue to demonstrate sustained improvements in blood glucose and weight with reduction in T2D medication utilization after a single Revita treatment No device- or procedure-related serious adverse events have...
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
BURLINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that Dr. Harith Rajagopalan,...
Source: https://incomestatements.info
Category: Stock Reports